双歧杆菌三联活菌肠溶胶囊对NAFLD患者的疗效及血清NO、内毒素、RBP4的影响-东南大学学报医学版

双歧杆菌三联活菌肠溶胶囊对NAFLD患者的疗效及血清NO、内毒素、RBP4的影响

单位：三亚市人民医院消化内科, 海南三亚 572000

分类号：R575.5

出版年·卷·期（页码）：2018·37·第一期（96-100）

摘要：

目的：探讨双歧杆菌三联活菌肠溶胶囊治疗非酒精性脂肪性肝病（NAFLD）患者的效果及对血清一氧化氮（NO）、内毒素、视黄醇结合蛋白4（RBP4）的影响。方法：选取2014年1月至2016年5月在我院治疗的NAFLD患者180例，采用SPSS16.0软件生成随机数字后分为研究组、对照组各90例，两组均采用常规保肝治疗，研究组加用双歧杆菌三联活菌肠溶胶囊，疗程12周。结果：治疗前，研究组的ALT、AST、GGT、TG、TC、IL-6、TNF-α、hs-CRP、NO、内毒素、RBP4水平与对照组差异无统计学意义（P>0.05）；治疗后，研究组的ALT、AST、GGT、TG、TC、IL-6、TNF-α、hs-CRP、NO、内毒素、RBP4水平均低于对照组（P<0.05）；研究组的治疗总有效率90.00%高于对照组的77.78%（P<0.05）。结论：双歧杆菌三联活菌肠溶胶囊治疗NAFLD患者具有减轻炎症反应、降低血清NO、内毒素、RBP4水平的作用，同时具有较好的保肝护肝功能。

Objective: To investigate the effect of Bifidobacterium triple live bacteria enteric-coated capsules on the treatment of NAFLD patients and the effect on serum NO,endotoxin and RBP4. Methods: 180 patients with NAFLD treated in our hospital from January 2014 to May 2016 were selected,Using SPSS16.0 software to generate random numbers into study group,control group,90 cases,both groups were treated with conventional liver protection,the study group with bifidobacterium triple live Enteric-coated capsules,treatment for 12 weeks. Results: The levels of ALT,AST,GGT,TG,TC,IL-6,TNF-α,hs-CRP,NO,endotoxin and RBP4 in the study group were not significantly different from those in the control group before treatment(P>0.05). After treatment,the levels of ALT,AST,GGT,TG,TC,IL-6,TNF-a,hs-CRP,NO,endotoxin and RBP4 in the study group were all lower than those of the control group(P<0.05). The total effective rate of treatment in the study group was 90% higher than that of the control group 77.78%(P<0.05). Conclusion: Bifid Triple Viable Capsules Dissolving at Intestines treatment can reduce inflammation,reduce serum NO,endotoxin and RBP4 levels in patients with NAFLD,and it has good hepatoprotective function.

参考文献：

[1] 邵敏娟,王新国,黄利华.桂利嗪改善肝脏循环对非酒精性脂肪性肝炎的治疗作用[J].中国新药与临床杂志,2016,35(6):427-431.
[2] 郭伟,高明松,李伟,等.二甲双胍联合双歧杆菌三联活菌胶囊对非酒精性脂肪肝病的治疗作用[J].中国新药杂志,2016,31(4):439-442.
[3] 巫协宁.非酒精性脂肪性肝炎肝细胞癌的发病机制[J].中华消化杂志,2015,35(2):77-79.
[4] TAKAHASHI Y,FUKUSATO T.Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].Metabolism,2015,191(2):235-240.
[5] LAMBERT J E,RAMOSROMAN M A,Browning J D,et al.Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.[J].Gastroenterology,2014,146(3):726-735.
[6] LOOMBA R,WOLFSON T,ANG B,et al.Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease:a prospective study.[J].Hepatology,2014,60(6):1920-1928.
[7] 田峰,周荣军,张京楠,等.降脂护肝汤调治非酒精性脂肪性肝炎的临床疗效[J].中国实验方剂学杂志,2016,31(7):182-186.
[8] 孙树申,杜绍山.双歧杆菌、嗜酸乳杆菌联合三联疗法根除幽门螺杆菌效果观察[J].山东医药,2014,29(34):39-40.
[9] 罗灵和,陈军贤,刘海燕,等.枯草杆菌肠球菌二联活菌对非酒精性脂肪性肝炎患者的干预作用[J].中华消化杂志,2014,34(12):852-853.
[10] 卢丹,龚大范,廖惠充,等.双歧杆菌四联活菌治疗非酒精性脂肪肝的疗效观察[J].广东医学,2016,37(8):1221-1222.
[11] 李豪,杨永志,袁耀宗,等.双歧杆菌三联活菌制剂治疗肠易激综合征临床疗效的Meta分析[J].中国实用内科杂志,2016,25(9):824-828.
[12] 毛立新,郭元春,钱剑.双歧杆菌三联活菌胶囊治疗溃疡性结肠炎的临床观察[J].中国药房,2015,26(36):5095-5096.
[13] 王巍,崔立红.利福昔明片联合双歧杆菌三联活菌胶囊治疗中老年急性感染性腹泻84例[J].中国新药杂志,2016,35(9):1036-1039.
[14] 曹伟,赵彩彦,王玮,等.双歧杆菌乳杆菌三联活菌对小鼠急性肝功能衰竭的保护作用及其分子机制[J].中华传染病杂志,2015,33(1):38-43.
[15] 周舟,陈小梅,李富强,等.活化胆碱能抗炎通路对非酒精性脂肪性肝炎炎症反应的抑制作用及其机制[J].中华肝脏病杂志,2015,23(1):64-68.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录